ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/KRAS-G12D-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/KRAS-G12D-inhibitor
9
trial(s) found.
NCT07659795
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203) (
TARGET-D-203
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Colorectal cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07644559
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201) (
VS-7375-201
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
anti-EGFR monoclonal antibody
Pancreatic adenocarcinoma
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07535112
Advanced
Phase 1
Recruiting
Master Protocol: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BAY 3771249 as Monotherapy or Combination With Other Cancer Treatments in Participants With Solid Tumors Harboring a KRAS G12D Mutation. Substudy Protocol: An Open-label, Multi-cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of BAY 3771249 as Monotherapy and in Combination With Cetuximab in Participants With Advanced/Metastatic Colorectal Adenocarcinoma Harboring a KRAS G12D Mutation (
23111-1
)
KRAS G12D inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
Colorectal adenocarcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT07522073
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (
DAWN-303
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Pancreatic adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07456046
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation (
D3S-003-100
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT07020221
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors (
VS-7375-101
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06619587
Advanced
Phase 1
Recruiting
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation (
GO45416
)
KRAS G12D inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NA
NA
NCT06179160
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (
INCB161734-101
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NCT06162221
Advanced
Phase 1 / Phase 2
Recruiting
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) (
RMC-LUNG-101
)
Carboplatin
Cisplatin
Daraxonrasib
Elironrasib
HRAS inhibitor
KRAS G12C inhibitor
KRAS G12C inhibitor,tricomplex inhibitor
KRAS G12D inhibitor
KRAS G12D inhibitor,tricomplex inhibitor
KRAS inhibitor
KRAS inhibitor,ON-state
KRAS inhibitor,mutant selective
KRAS inhibitor,tricomplex inhibitor
NRAS inhibitor
Pembrolizumab
Pemetrexed
Zoldonrasib
anti-PD-1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,KRAS-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
pan-KRAS inhibitor
pan-RAS inhibitor
pan-RAS inhibitor,tricomplex inhibitor
platinum-based antineoplastic agent
+ KRAS G12D inhibitor
Cancer
Lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (9)
Recruitment Country and State
NSW (6)
VIC (6)
SA (3)
WA (3)
QLD (2)
ACT (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (1)
Trial Type
Advanced (9)
Cancer Therapy Class
KRAS
100%
EGFR
56%
PD-1
33%
PD-1/PD-L1
33%
TGFBR2
11%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2170 - Liverpool - Liverpool Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
6009 - Nedlands - Linear Clinical Research (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2605 - Garran - The Canberra Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
NA
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Colorectal adenocarcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy